Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

CAR-T Meeting 2020 | Cost-effectiveness of CAR T-cell therapy

Carin Al Uyl-de Groot • 12 Feb 2020
CAR-T Meeting 2020
Acute Lymphoblastic Leukemia Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T

Carin Al Uyl-de Groot, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands, discusses the evaluation of the cost-effectiveness of CAR T-cell therapy for pediatric acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

More from Carin Al Uyl-de Groot

Pre- and post-CAR T-cell therapy costs
0:54
Pre- and post-CAR T-cell therapy costs
Carin Al Uyl-de Groot • 30 Jan 2020

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Carin Al Uyl-de Groot • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Carin Al Uyl-de Groot • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Carin Al Uyl-de Groot • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Carin Al Uyl-de Groot • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals